» Articles » PMID: 29349760

Advancements and Personalization of Breast Cancer Treatment Strategies in Radiation Therapy

Overview
Publisher Springer
Specialties Oncology
Pharmacology
Date 2018 Jan 20
PMID 29349760
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Significant technologic advances in radiation treatment delivery now allow for more personalized delivery considerations which incorporate individual patient characteristics (such as tumor location and patient anatomy) and more precise delivery in the breast conservation or post-mastectomy setting. The combined advancements with other treatment modalities (i.e., systemic therapy, surgical management) have had direct effects on local-regional management and outcomes such that currently, local-regional relapses after definitive treatment for localized disease are now rarely experienced. Recent advances in the radiation therapy field have come from careful patient selection for a variety of three-dimensional treatment delivery techniques and alternatives to conventional tangential radiation. These advances have been demonstrated to diminished acute/long-term toxicity, minimized dose to surrounding normal tissue structures such as the heart and lung, and ultimately result in an improvement in the therapeutic ratio for radiation treatment. This chapter discusses recent radiation innovations and appropriate patient selection for their application, for a more personalized approach to radiation therapy for breast cancer patients.

Citing Articles

Advances in Ultrasound-Targeted Microbubble Destruction (UTMD) for Breast Cancer Therapy.

Wu Y, Liu Y, Wu H, Tong M, Du L, Ren S Int J Nanomedicine. 2025; 20:1425-1442.

PMID: 39925678 PMC: 11804227. DOI: 10.2147/IJN.S504363.


Identification of potential biomarkers and metabolic pathways based on integration of metabolomic and transcriptomic data in the development of breast cancer.

Yang Y, Zhu Y, Li X, Zhang X, Yu B Arch Gynecol Obstet. 2021; 303(6):1599-1606.

PMID: 33791842 DOI: 10.1007/s00404-021-06015-9.


Differences in the Expression Pattern of mRNA Protein SEMA3F in Endometrial Cancer under Cisplatin Treatment.

Kieszkowski P, Dabrus D, Grabarek B, Boron D Curr Pharm Biotechnol. 2020; 21(11):1119-1128.

PMID: 32297576 PMC: 7536788. DOI: 10.2174/1389201021666200416102540.


Upregulation of SHIP2 participates in the development of breast cancer via promoting Wnt/β-catenin signaling.

Zhou J, Di M, Han H Onco Targets Ther. 2019; 12:7067-7077.

PMID: 31564892 PMC: 6722435. DOI: 10.2147/OTT.S223422.


Is Proton Therapy a "Pro" for Breast Cancer? A Comparison of Proton vs. Non-proton Radiotherapy Using the National Cancer Database.

Chowdhary M, Lee A, Gao S, Wang D, Barry P, Diaz R Front Oncol. 2019; 8:678.

PMID: 30693271 PMC: 6339938. DOI: 10.3389/fonc.2018.00678.